Ixabepilone‐induced mitochondria and sensory axon loss in breast cancer patients
Annals of Clinical and Translational Neurology2014Vol. 1(9), pp. 639–649
Citations Over TimeTop 13% of 2014 papers
Gigi J. Ebenezer, Karen-Sue Carlson, Diana Donovan, Marta Vallee Cobham, Ellen Chuang, Anne Moore, Tessa Cigler, Maureen M. Ward, Maureen E. Lane, Anita Ramnarain, Linda T. Vahdat, Michael Polydefkis
Abstract
This study provides functional and structural evidence that Ix exposure induces a dose-dependent toxicity on small sensory fibers with an increase in TNSc scores and progressive axonal loss. Mitochondria appear to bear the cumulative toxic effect and chemotherapy-induced toxicity can be monitored through serial skin biopsy-based analysis.
Related Papers
- Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.(2008)
- → Advances in breast cancer treatment: the emerging role of ixabepilone(2009)8 cited
- → Ixabepilone, a novel epothilone analog in the treatment of breast cancer(2008)16 cited
- → The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies(2009)7 cited
- → Clinical Experience with Epothilones in Patients with Breast Cancer(2008)6 cited